+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 17 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating a new combined approach to improve new learning and memory NLM in people with multiple sclerosis pwMS who have mobility difficulties. This study looks at how combining cognitive rehabilitation using the Kessler Foundation modified Story Memory Technique KF-mSMT, a memory retraining program, with exercise may enhance recovery more than cognitive rehabilitation alone. The study aims to maximize functional recovery by addressing the limitations of cognitive rehabilitation when used by itself. Participants will be randomly assigned to one of two groups. One group will complete a supervised aerobic exercise training program with virtual reality IDEAL three days a week for 12 weeks for the first seven weeks, they do only the exercise, and for weeks 8 to 12, they also do the KF-mSMT memory program two days a week. The other group will do supervised stretching and toning exercises three days a week for 12 weeks, with the same schedule of adding KF-mSMT during weeks 8 to 12. Both interventions are supervised and aim to improve memory and physical activity. Participants will be assessed before the intervention weeks 1 and 2 and after the intervention weeks 15 and 16 to measure changes in objective learning and memory, everyday memory, and brain changes such as hippocampal volume and function. The study includes questionnaires and memory tests, with safety and progress monitored throughout. Participation lasts about 16 weeks in total, including the treatment and follow-up assessments.

Age: 18Years - 70YearsAll GendersPhase Not Applicable
1 location
R

Actively Recruiting

Researchers are evaluating the real-world effectiveness and patient-centered outcomes of remibrutinib in adults with chronic spontaneous urticaria CSU, a condition characterized by spontaneous hives and itching. This prospective, non-interventional study compares patients starting remibrutinib treatment to those starting dupilumab, using validated patient reported outcome tools to measure results. The study is based in the United States and sponsored by Novartis Pharmaceuticals. Participants include adult patients diagnosed with CSU who have been prescribed remibrutinib or dupilumab and are expected to start treatment. The study observes two groups one receiving remibrutinib and the other dupilumab. The treatments are not administered by the study but are prescribed by healthcare providers as part of routine care. The study does not involve drug administration or placebo controls, focusing instead on real-world outcomes and patient satisfaction. During the study, participants use electronic devices to complete assessments including the Urticaria Control Test UCT-7 at baseline, week 1, and week 4 to measure symptom control. Treatment satisfaction is measured with the Treatment Satisfaction Questionnaire for Medication TSQM-9 at baseline and week 4. Researchers will monitor changes in these scores to understand treatment impact and patient satisfaction. The study requires participants to be able to read English and provide consent, with ongoing data collection continuing until the study ends in September 2026.

Age: 18Years - 100YearsAll Genders
1 location
S

Actively Recruiting

Researchers are studying a strength-based employment program designed to help young adults on the autism spectrum improve their job maintenance skills. This program focuses on using individual strengths rather than correcting deficits, responding to the autism communitys call for more positive and holistic approaches. The study aims to evaluate how effective this approach is in improving work satisfaction and the ability to keep jobs among young adults with autism. Participants in the study are randomly assigned to one of two groups one group receives the strength-based training called KF-STRIDE Into Work, which consists of 10 web-based sessions lasting about 60 minutes each, delivered once or twice a week. The other group continues with their usual services and regular activities without the additional intervention. This randomized, single-masked study compares the outcomes between these two groups. Throughout the study, participants complete various assessments before and immediately after the intervention period of seven to eight weeks. These include questionnaires about employment, self-efficacy, strengths use, flourishing, resilience, work satisfaction, and self-esteem. Researchers also gather participant impressions of change and evaluate job search skills. The study monitors these measures to understand the programs impact on job maintenance skills in autistic young adults.

Age: 14Years - 26YearsAll GendersPhase Not Applicable
1 location
C

Actively Recruiting

Researchers are evaluating the real-world effectiveness and economic impact of two treatments, ofatumumab OMB and ocrelizumab OCR, in people diagnosed with multiple sclerosis MS in the United States. The study aims to compare how well these treatments reduce the annualized relapse rate ARR and to assess related healthcare use and costs. Data will be gathered from de-identified healthcare claims collected over time to better understand these outcomes. The study includes multiple groups patients new to treatment who start OMB or OCR without prior disease-modifying therapy DMT use in the past year, as well as all patients starting OMB or OCR regardless of previous treatment. Participants are grouped based on their treatment claims, and the study observes their healthcare utilization and relapse events over approximately five years and four months. Participants health records will be analyzed to measure relapse rates, healthcare visits, and costs yearly. The main focus is on treatment-naive patients, with several secondary measures including time to first relapse and total healthcare expenses. Continuous healthcare enrollment and persistent medication use for at least six months are required. The study spans a long period, allowing in-depth observation of treatment effects and economic burden in real-world settings.

Age: 18Years - 100YearsAll Genders
1 location
P

Actively Recruiting

Researchers are evaluating treatment preferences among adults with Primary Immune Thrombocytopenia ITP in the United States. This observational study aims to understand what treatment features matter most to patients receiving either first-line or second-line therapies. The study is conducted by Novartis Pharmaceuticals and involves a preference elicitation survey to collect patient perspectives. The study has two stages. The first stage focuses on developing the survey and identifying key treatment attributes relevant to patients. The second stage involves administering the finalized survey to adult participants currently treated for ITP, followed by detailed analysis of the collected data to assess how treatment preferences vary with personal characteristics and risk-benefit trade-offs. Participants will complete a survey capturing their preferences related to ITP treatment options. Researchers will analyze preference weights for treatment attributes, acceptable risks, and benefits for each participant. The study involves no drug administration or medical intervention and will last from December 2025 to December 2026. Data collection and analysis aim to provide insights into patient-centered treatment decision-making for ITP.

Age: 18Years +All Genders
1 location
R

Actively Recruiting

Researchers are studying adults with metastatic castration-resistant prostate cancer mCRPC in the United States to understand treatment patterns, clinical outcomes, and patient characteristics in real-world medical practice. The study uses data from the PRECISION data platform, focusing on how patients are treated and how they respond over time. The study observes adult male patients recently diagnosed with mCRPC, analyzing their prior and ongoing therapies without assigning any new treatments. Data collected includes types of therapies used at different lines of treatment, changes in therapy, and timing related to therapy initiation and switching, covering a period of up to approximately five years. Participants medical records and data from the PRECISION platform are reviewed to measure outcomes such as the number and type of treatments, time to treatment start, progression-free survival, and overall survival. The research team monitors these outcomes over up to five years to better understand real-world treatment experiences and results for men with mCRPC.

Age: 18Years - 115YearsMALE
1 location
R

Actively Recruiting

Researchers are studying adults with metastatic castration-resistant prostate cancer mCRPC who have already been treated with at least one androgen receptor pathway inhibitor ARPI, one taxane chemotherapy, and Lutetium-177 Vipivotide Tetraxetan 177Lu-PSMA-617 in real-world clinical settings in the United States. This observational study uses data from the PRECISION data platform to understand treatment patterns, patient characteristics, and clinical outcomes for these patients. The study observes patients with a confirmed diagnosis of mCRPC who have evidence of prior treatments with ARPI, taxane chemotherapy, and 177Lu-PSMA-617 starting from January 1, 2021. Participants are grouped into an overall cohort, a subgroup with disease progression after 177Lu-PSMA-617 treatment, and a subgroup initiating at least one new systemic therapy after the index date, which is defined by the last treatment received among the specified therapies. Participants data will be analyzed for various outcomes including the number and types of therapies received before and after the index date, timing and frequency of prostate-specific membrane antigen PSMA scans, progression-free survival, overall survival, and changes in prostate-specific antigen PSA levels. This observational study will follow participants data for up to approximately five years, with no active treatment administered as part of the study.

Age: 18Years - 115YearsMALE
1 location
O

Actively Recruiting

Researchers are studying treatment patterns and clinical outcomes in adults newly diagnosed with gastroenteropancreatic neuroendocrine tumors GEP-NET in the United States. This observational study uses open-source prescription and medical claims data, along with mortality information, to understand how treatments are being used and their effects over time. The study is sponsored by Novartis Pharmaceuticals and aims to provide real-world insights into GEP-NET management. The study includes several patient groups based on the treatments they receive, such as first-line therapies with lutetium Lu 177 dotatate, CAPTEM capecitabine plus temozolomide, cabozantinib, and these treatments when given in second-line or later settings. Researchers will track the number of therapy lines, treatment regimens, therapy types, discontinuations, and treatment cycles over about eight years. No investigational drugs are administered directly as this is an observational study. Participants data will be reviewed for up to eight years to measure outcomes like time to treatment discontinuation, treatment switching, overall survival, and demographic and clinical characteristics. The study examines claims data before and after diagnosis and treatment initiation, focusing on real-world clinical outcomes. This long-term observation will help characterize treatment durations, switches, and survival outcomes among GEP-NET patients.

Age: 18Years - 110YearsAll Genders
1 location
R

Actively Recruiting

Researchers are investigating the impact of two different online group wellness treatments for individuals living with chronic mild traumatic brain injury TBI, moderate to severe TBI, and Alzheimers disease or related dementias ADRD, as well as their support persons. The study aims to compare these treatments to improve self-efficacy and quality of life, understand how patient neurobehavioral functioning influences caregiver outcomes, and identify biomarkers that predict treatment success. This research is conducted across three sites, each focusing on a specific patient group, and is coordinated by Kessler Foundation. Participants engage in one of two group wellness classes, each involving twelve weekly online sessions lasting about two hours. These sessions are designed for both individuals with the neurological conditions and their support persons. The study groups run in parallel, and treatments are behavioral interventions delivered remotely to facilitate participation. The research spans 12 weeks of active intervention, followed by ongoing assessments. Throughout the study, participants complete measures such as the Self-Efficacy Questionnaire and the Satisfaction with Life Scale at the start, after 12 weeks of treatment, and again at a 6-month follow-up. Caregiver burden and various neural, behavioral, and blood biomarkers are also evaluated to assess treatment effects and predict outcomes. Participants can expect regular online group sessions, questionnaires, and ongoing monitoring over the course of the trial, which is expected to conclude in September 2027.

Age: 18Years +All GendersPhase Not Applicable
1 location
R

Actively Recruiting

Researchers are evaluating KF-STRIDE 3.0, a behavioral program adapted to help adults with autism improve their job interview skills. This study aims to refine the intervention, originally designed for youth, to better meet the needs of adults on the spectrum. The goal is to support employment, which can enhance community integration and social connections for adults with autism. Participants will be randomly assigned to receive either the KF-STRIDE intervention, which focuses on recognizing personal strengths and expressing them appropriately in job interviews, or continue with their usual services. The study will use community feedback to guide modifications and will assess the programs acceptability, feasibility, fidelity, and initial effectiveness. During the study, participants will complete assessments including a 20-minute video-recorded mock job interview, the Autism Mock Interview Rating-Scale, the Work Readiness Scale, and employment status measurements at baseline and after 7 to 8 weeks. Quality of life will also be evaluated. The study runs from January 2026 through July 2027, with outcomes measured immediately after the intervention period.

Age: 18Years - 65YearsAll GendersPhase Not Applicable
1 location

1-10 of 17

1